INIS
patients
100%
sri lanka
91%
diseases
73%
nervous system diseases
71%
resources
48%
atrophy
39%
gene therapy
39%
developing countries
32%
amplification
30%
probes
30%
prediction
29%
genes
29%
phenotype
29%
polymerase chain reaction
29%
reviews
29%
performance
29%
assessments
29%
asia
29%
pathology
29%
clinical trials
29%
biodiversity
29%
symptoms
29%
populations
21%
exons
19%
charges
19%
cost
19%
variations
19%
proteins
17%
information
17%
biological availability
14%
Keyphrases
Duchenne muscular Dystrophy
88%
Sri Lanka
68%
Molecular Diagnostics
65%
Huntington's Disease
36%
Spinal muscular Atrophy
36%
Gene Therapy
36%
South Asian
36%
Spinocerebellar Ataxia
30%
Neurogenetics
29%
Phenotype Prediction
29%
Study Review
29%
Therapeutic Implications
29%
Resource-limited Settings
29%
Neuroimmune Diseases
29%
Diagnostic Performance
29%
Diagnostic Services
29%
Dystrophinopathy
29%
Wealth Creation
29%
Natural Products
29%
Integrated Genomics
29%
South Asia
29%
Multicenter Clinical Trial
29%
Genomics-proteomics
29%
Cognitive Assessment
29%
Trinucleotide Repeat Diseases
29%
Astrocytes
29%
Plant Back
29%
Developing Countries
22%
Multiplex Ligation-dependent Probe Amplification
19%
Limited Resources
17%
Neuroscience
Muscular Dystrophy
88%
Natural Product
46%
Proteomics
29%
Astrocyte
29%
Neuroprotective Agent
29%
Trinucleotide Repeat Disorder
29%
Transcription Factor Nrf2
29%
Neuromuscular
29%
Huntington's Disease
24%
Spinal Muscular Atrophy
24%
Spinocerebellar Ataxia
16%
Alzheimer's Disease
15%
Multiplex Ligation-Dependent Probe Amplification
15%
Multiplex Polymerase Chain Reaction
11%
Nervous System Disorder
8%
Exon
7%
Neuromuscular Disorder
6%